We focused on sodium-glucose cotransporter-2 inhibitors (SGLT2is), a class of medications used to manage type 2 diabetes mellitus (T2DM) as well as heart failure and kidney disease. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.